NAS
TGTX icon

Nykredit A/S’s TG Therapeutics TGTX Stock Holding History

Nykredit A/S’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Buy
+4,767
New +$195K ﹤0.01% 932

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Nykredit A/S's TGTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in TG Therapeutics (TGTX) in Q2 2026: 4,767 shares worth $262K. The stake represents ﹤0.01% of the portfolio and ranks #932 among its holdings.

333 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Nykredit A/S held 4,767 shares of TG Therapeutics worth $262K as of Q2 2026.
  • TG Therapeutics was a new Nykredit A/S position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #932 holding.
  • 333 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.